Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy

被引:160
作者
Dore, GJ
McDonald, A
Li, YM
Kaldor, JM
Brew, BJ
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
[2] St Vincents Hosp, HIV Immunol Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia
[3] St Vincents Hosp, Dept Neurol, Sydney, NSW 2010, Australia
关键词
HIV; AIDS dementia complex; antiretroviral therapy;
D O I
10.1097/00002030-200307040-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the effect of introduction of highly active antiretroviral therapy (HAART) on survival following AIDS dementia complex (ADC). Methods: Australian AIDS notification data in the period 1993-2000 were examined. In order to examine the impact of HAART, two periods of AIDS diagnoses were chosen: pre-HAART (1993-1995) and HAART (1996-2000). Median survival was based on Kaplan-Meier estimates, with examination of factors influencing survival in a Cox proportional hazards model. Results: In the period 1993-2000 in Australia, 5017 initial AIDS illnesses were diagnosed among 4351 AIDS patients. The proportion of AIDS cases with ADC increased from 5.2% in 1993-1995 to 6.8% in 1996-2000 (P=0.029). Median survival following AIDS increased from 19.6 months for those diagnosed with AIDS in 1993-1995 to 39.6 months for those diagnosed in 1996-2000 (P < 0.0005). Median survival following ADC increased to a greater extent than that for all other AIDS illnesses, from 11.9 months in 1993-1995 to 48.2 in 1996-2000 (P < 0.0005). Most striking was the increase in survival among those with ADC and a CD4 cell count < 100 x 10(6) cells/l at diagnosis; 5.1 months in 1993-1995 to 38.5 months in 1996-2000 (P < 0.0005). Conclusion: Although there has been a proportional increase in ADC at AIDS diagnosis, survival following ADC has improved markedly in the era of HAART. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1539 / 1545
页数:7
相关论文
共 44 条
  • [21] Progressive multifocal leukoencephalopathy: Improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era
    Dworkin, MS
    Wan, PCT
    Hanson, DL
    Jones, JL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) : 621 - 625
  • [22] Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
    Egger, M
    Hirschel, B
    Francioli, P
    Sudre, P
    Wirz, M
    Flepp, M
    Rickenbach, M
    Malinverni, R
    Vernazza, P
    Battegay, M
    Bernasconi, E
    Burgisser, P
    Erb, P
    Fierz, W
    Grob, P
    Gruninger, U
    Jeannerod, L
    Ledergerber, B
    Luthy, R
    Matter, L
    Opravil, M
    Paccaud, F
    Perrin, L
    Pichler, W
    Piffaretti, GC
    Rutschmann, O
    Zanetti, G
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117): : 1194 - 1199
  • [23] HIV-protease inhibitors
    Flexner, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) : 1281 - 1292
  • [24] Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
    Foudraine, NA
    Hoetelmans, RMW
    Lange, JMA
    de Wolf, F
    van Benthem, BHB
    Mass, JJ
    Keet, IPM
    Portegies, P
    [J]. LANCET, 1998, 351 (9115) : 1547 - 1551
  • [25] Survival after AIDS diagnosis in a cohort of hemophilia patients
    Gail, MH
    Tan, WY
    Pee, D
    Goedert, JJ
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 15 (05): : 363 - 369
  • [26] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
    Hammer, SM
    Squires, KE
    Hughes, MD
    Grimes, JM
    Demeter, LM
    Currier, JS
    Eron, JJ
    Feinberg, JE
    Balfour, HH
    Dayton, LR
    Chodakewitz, JA
    Fischl, MA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 725 - 733
  • [27] A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
    Hammer, SM
    Katzenstein, DA
    Hughes, MD
    Gundacker, H
    Schooley, RT
    Haubrich, RH
    Henry, WK
    Lederman, MM
    Phair, JP
    Niu, M
    Hirsch, MS
    Merigan, TC
    Blaschke, TF
    Simpson, D
    McLaren, C
    Rooney, J
    Salgo, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) : 1081 - 1090
  • [28] Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
    Hogg, RS
    Heath, KV
    Yip, B
    Craib, KJP
    O'Shaughnessy, MV
    Schechter, MT
    Montaner, JSG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (06): : 450 - 454
  • [29] Holtzer CD, 1998, AIDS, V12, P1931
  • [30] Predicting survival in AIDS: refining the model
    Hutchinson, SJ
    Brettle, RP
    Gore, SM
    [J]. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1997, 90 (11): : 685 - 692